MX378004B - Composición oral veterinaria con gabapentina. - Google Patents

Composición oral veterinaria con gabapentina.

Info

Publication number
MX378004B
MX378004B MX2015016589A MX2015016589A MX378004B MX 378004 B MX378004 B MX 378004B MX 2015016589 A MX2015016589 A MX 2015016589A MX 2015016589 A MX2015016589 A MX 2015016589A MX 378004 B MX378004 B MX 378004B
Authority
MX
Mexico
Prior art keywords
composition
gabapentin
sorbitan
combinations
total weight
Prior art date
Application number
MX2015016589A
Other languages
English (en)
Other versions
MX2015016589A (es
Inventor
Navarrete Cliserio Pérez
Auerbach Jaime Samuel Chait
Original Assignee
Jaime Samuel CHAIT AUERBACH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jaime Samuel CHAIT AUERBACH filed Critical Jaime Samuel CHAIT AUERBACH
Priority to MX2015016589A priority Critical patent/MX378004B/es
Priority to US16/076,578 priority patent/US10610498B2/en
Priority to PCT/MX2016/000124 priority patent/WO2017095214A1/es
Priority to EP16871109.1A priority patent/EP3384907B1/en
Publication of MX2015016589A publication Critical patent/MX2015016589A/es
Publication of MX378004B publication Critical patent/MX378004B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica veterinaria sólida, de administración oral que comprende: a) fármaco seleccionado de gabapentina y/o fluoxetina o una sal farmacéuticamente aceptable de los mismos, preferentemente gabapentina o una sal aceptable del mismo en una concentración de 10 a 1000 mg; b) de 10% al 80% del peso total de la composición de al menos una sal de silicio seleccionado de manera preferente de dióxido de silicio, dióxido de silicio coloidal, silicato de calcio, silicato de magnesio o combinaciones de los mismos; c) de 1% al 20% del peso total de la composición de al menos un éster polioxietilenado de sorbitán, seleccionado de manera preferente de monolaurato de sorbitán, monooleato de sorbitán y trioleato de sorbitan, o combinaciones de los mismos; y d) uno o más excipientes farmacéuticamente aceptables; tal que se prepara de manera óptima como un producto farmacéutico veterinario que presenta seguridad y eficacia en animales mamíferos, preferentemente en animales de compañia.
MX2015016589A 2015-12-02 2015-12-02 Composición oral veterinaria con gabapentina. MX378004B (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
MX2015016589A MX378004B (es) 2015-12-02 2015-12-02 Composición oral veterinaria con gabapentina.
US16/076,578 US10610498B2 (en) 2015-12-02 2016-12-02 Oral veterinary composition with gabapentin
PCT/MX2016/000124 WO2017095214A1 (es) 2015-12-02 2016-12-02 Composición oral veterinaria con gabapentina
EP16871109.1A EP3384907B1 (en) 2015-12-02 2016-12-02 Oral veterinary composition with gabapentin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2015016589A MX378004B (es) 2015-12-02 2015-12-02 Composición oral veterinaria con gabapentina.

Publications (2)

Publication Number Publication Date
MX2015016589A MX2015016589A (es) 2017-06-01
MX378004B true MX378004B (es) 2025-03-10

Family

ID=58797399

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016589A MX378004B (es) 2015-12-02 2015-12-02 Composición oral veterinaria con gabapentina.

Country Status (4)

Country Link
US (1) US10610498B2 (es)
EP (1) EP3384907B1 (es)
MX (1) MX378004B (es)
WO (1) WO2017095214A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3900715A1 (en) * 2020-04-21 2021-10-27 Dompe' Farmaceutici S.P.A. Synergistic admixtures of gabapentin and ketoprofen, pharmaceutical compositions and their medical use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012537A1 (en) 1997-09-08 1999-03-18 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
US20030013740A1 (en) * 1998-03-27 2003-01-16 Martin P. Redmon Stable dosage forms of fluoxetine and its enantiomers
US6451857B1 (en) 1999-03-10 2002-09-17 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
US20050158380A1 (en) * 2002-06-07 2005-07-21 Manish Chawla Sustained release oral dosage forms of gabapentin
WO2004091278A2 (en) * 2003-04-11 2004-10-28 Transform Pharmaceuticals, Inc. Gabapentin compositions
AU2006248645A1 (en) 2005-05-20 2006-11-23 Pfizer Limited Synergistic combinations of non-steroidal antiinflammatory drugs with alpha-delta-ligands
MX2008016349A (es) * 2006-06-19 2009-01-28 Accu Break Technologies Inc Formas segmentadas de dosificacion farmaceutica.
WO2008008120A1 (en) * 2006-07-14 2008-01-17 Fmc Corporation Solid form
US8791105B2 (en) 2010-07-14 2014-07-29 Kansas State University Research Foundation Methods for alleviating chronic pain and improving performance of cattle undergoing dehorning or castration
MA39272A (fr) * 2014-04-09 2015-10-14 Arven Ilac Sanayi Ve Ticaret As Formulations à libération prolongée de gabapentine

Also Published As

Publication number Publication date
US20190046475A1 (en) 2019-02-14
WO2017095214A1 (es) 2017-06-08
US10610498B2 (en) 2020-04-07
MX2015016589A (es) 2017-06-01
EP3384907B1 (en) 2026-03-25
EP3384907A4 (en) 2019-06-05
EP3384907A1 (en) 2018-10-10

Similar Documents

Publication Publication Date Title
CY1124052T1 (el) Δισκιο διασπειρομενο στο στομα περιεχον οιστετρολη
ZA201800022B (en) Substituted heterocyclyl derivatives as cdk inhibitors
EP3207931A3 (en) Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies
MX2018009158A (es) Compuestos organicos.
MX2023006541A (es) Formulaciones de dosis fija.
PH12019502150A1 (en) Compounds and methods for the treatment of parasitic diseases
MX394588B (es) Composición farmacéutica.
MX2017007651A (es) Combinacion farmaceutica que comprende un agonista selectivo del receptor s1p1.
EA201691789A1 (ru) Фармацевтические композиции и соли 1,2,4-оксадиазолбензойной кислоты
PH12017500029A1 (en) 4,5-dihydroisoxazole derivatives as nampt inhibitors
MA40781A (fr) Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie orale
MY182008A (en) Pharmaceutical formulations
MX378004B (es) Composición oral veterinaria con gabapentina.
MX385513B (es) Composiciones farmaceuticas que comprenden safinamida.
EP3326628A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION WITH HIGH-CONCENTRATED TAXAN
MX370184B (es) Composición farmacéutica que comprende fingolimod.
CL2020003153A1 (es) Composiciones antimicrobianas con agentes efervescentes (divisional de solicitud n° 03273-2016)
MX386932B (es) Proceso para formulaciones sólidas de mesalazina.
EA201692536A1 (ru) Диспергируемая таблетка мизопростола
PH12016502527A1 (en) Stabilized desmopressin
EA201691763A1 (ru) Стабильная быстрорастворимая лекарственная форма, содержащая амоксициллин и клавулановую кислоту
IL291149A (en) Pharmaceutical formulations of indoleamine 2, 3 dioxygenase inhibitors
EA201691599A1 (ru) Комбинация таурина и рацеметионина для лечения заболеваний печени
JP2016204346A5 (es)
MX2015009504A (es) Composicion farmaceutica de desloratadina para ser administrada por via oral, para el tratamiento de enfermedades relacionadas con la histamina.